Biotech & Life Sciences

Biotech marketing for investor relations, scientific communications, and commercial readiness

Empire325 is a biotech marketing agency for pre-clinical, clinical, and commercial-stage biotech, pharma, medtech, and diagnostics companies. We build investor relations programs, scientific communications, KOL engagement, and growth marketing — respecting FDA promotional rules, SEC fair disclosure requirements, and clinical-trial blackout periods.

Book a 15-min biotech strategy call

TL;DR: Empire325 biotech marketing combines investor relations, scientific communications, KOL engagement, and commercial-readiness marketing. Every engagement respects FDA, SEC, MLR, and quiet-period constraints — built alongside your regulatory counsel, not around them.

What Empire325 delivers in biotech

01

Investor relations

IR site builds, quarterly earnings communications, IPO/SPAC roadshow support, fact sheets, pipeline trackers, and investor-day materials. Reg-FD aligned.

02

Scientific communications

Pipeline narrative, MOA explainers, publication strategy support, conference presentations, and KOL-facing content. Scientific accuracy under MLR review.

03

KOL programs

Key Opinion Leader identification, advisory board support, scientific symposia, peer-to-peer education programs. Aligned with corporate compliance and Sunshine Act reporting.

04

Commercial readiness

Pre-launch market shaping, payer-facing content, HCP digital presence, patient-advocacy partnerships. Designed for the 12-24 months before approval.

05

Partnership / BD marketing

Pharma-partnership marketing for licensing, collaboration, and M&A. Positioning content for BD conversations at JPM Healthcare, BIO, AACR, ASH, ASCO.

06

Compliance-aware analytics

Marketing attribution that respects HIPAA where applicable, plus PII/PHI handling appropriate to the buyer audience (HCP, patient, investor, partner).

Biotech marketing FAQ

What does a biotech marketing agency do?

A biotech marketing agency builds investor relations programs, scientific communications, KOL (Key Opinion Leader) engagement, and commercial-readiness marketing for biotech, pharma, and life sciences companies. Empire325 biotech engagements span pre-clinical positioning, clinical milestone communications, IPO/SPAC roadshow support, partnership marketing, and (post-approval) commercial launch programs.

What's different about biotech marketing vs. typical B2B?

Three differences: (1) Audiences are highly technical (PIs, KOLs, regulators, institutional investors) requiring scientific accuracy, not consumer-style positioning. (2) Communications must respect SEC fair disclosure rules, FDA promotional restrictions, and clinical trial blackout periods. (3) Long timelines — pre-clinical to commercial can take 7-15 years, requiring sustained narrative investment without short-term traffic metrics as proof.

How does Empire325 handle FDA/SEC compliance in biotech marketing?

Every campaign and content piece enters a documented review pipeline aligned with the company's regulatory and legal counsel. We work alongside MLR (Medical/Legal/Regulatory) review teams, not around them. For investor-facing communications, we respect Reg FD, IPO quiet periods, and SEC Marketing Rule applicable provisions.

What biotech segments does Empire325 serve?

Pre-clinical and clinical-stage biotech, biopharmaceutical companies, medical device firms, diagnostics companies, contract research organizations (CROs), AI-drug-discovery platforms, gene therapy and cell therapy companies, and biotech-focused investors (VC funds, biotech hedge funds).

How much does biotech marketing cost?

Empire325 biotech engagements typically range $20K-$100K monthly retainers depending on scope, regulatory complexity, and IR/commercial mix. Implementation projects (IR site rebuilds, KOL programs, IPO marketing infrastructure) range $40K-$250K project-based. Discovery scoping is provided after a 30-minute call.

Want biotech marketing aligned to your regulatory team?

Book a 15-min strategy call

From our blog

Further reading

13 min read

Production RAG in 2026: Architecture Patterns That Survive Real-World Use

Retrieval-Augmented Generation looks easy in demos. Production RAG that survives real users requires deliberate decisions about chunking, embedding, retrieval, reranking, and evaluation.

10 min read

First-Party Data Strategy in a Cookieless 2026: The B2B Playbook

First-party data is now the only durable foundation for personalization, attribution, and audience activation. Most B2B brands haven't built the infrastructure yet.

14 min read

Enterprise Data Transformation Roadmap: A 90-180 Day Plan for 2026

Most enterprise data transformation projects stall in proof-of-concept purgatory. The 90-180 day roadmap that ships production-grade infrastructure — and avoids the $2M consulting black hole.

Go deeper across the site